Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Anal Cell Pathol (Amst). 2018 Mar 7;2018:9718585. doi: 10.1155/2018/9718585. eCollection 2018.

Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma.

Author information

1
Department of Molecular Medicine, Circulating Tumor Cells Unit, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
2
Policlinico Umerto I, II Division of Internal Medicine and Geriatrics, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
3
Department of Radiological, Oncological and Anatomopathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
4
Department of Movement, Human and Health Sciences, Division of Health Sciences, Foro Italico University of Rome, Piazza Lauro De Bosis 6, 00135 Rome, Italy.
5
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Via Alfonso Borelli 50, 00161 Rome, Italy.

Abstract

Hemangiopericytoma (HPT) is a rare mesenchymal tumor of fibroblastic type and for its rarity is poorly studied. The most common sites of metastatic disease in patients with intracranial HPT are the bone, liver, and lung, suggestive for an hematogenous dissemination; for this reason, we investigated, for the first time, the presence of circulating tumor cells (CTCs) in hemangiopericytoma patient by CellSearch® and SceenCell® devices. Peripheral blood samples were drawn and processed by CellSearch, an EpCAM-dependent device, and ScreenCell®, a device size based. We found nontypical CTCs by CellSearch system and the immunofluorescence analysis performed on CTCs isolate by ScreenCell demonstrated the presence of single CTCs and CTC clusters. The molecular characterization of single CTCs and CTC clusters, using antibodies directed against EpCAM, CD34, cytokeratins (8, 18, and 19), and CD45, showed a great heterogeneity in CTC clusters. We believe that the present study may open a new scenario in the rare tumors: the introduction of the liquid biopsy and the molecular characterization of circulating tumor cells could lead to personalized targeted treatments and also for rare tumors.

PMID:
29707475
PMCID:
PMC5863319
DOI:
10.1155/2018/9718585
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center